TG Therapeutics Inc. (TGTX) Business Metric Overview

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

TG Therapeutics Inc. (TGTX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

30.99

1.25 (4.20%)

At close: Jan 15, 2025, 9:58 AM

TG Therapeutics Inc. Revenue Breakdown

Quarter	Sep 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2021	Mar 31, 2021
License Revenue Revenue	38.00K	38.00K	66.94M	25.07M	1.51M	755.00K
License Revenue Revenue Growth	0.00%	-99.94%	+167.02%	+1563.44%	+99.60%	n/a
Other Revenue Revenue	315.00K	415.00K	n/a	n/a	n/a	n/a
Other Revenue Revenue Growth	-24.10%	n/a	n/a	n/a	n/a	n/a
Product Revenue	83.30M	50.49M	n/a	n/a	n/a	n/a
Product Revenue Growth	+64.98%	n/a	n/a	n/a	n/a	n/a
Royalty Revenue	229.00K	33.00K	n/a	n/a	n/a	n/a
Royalty Revenue Growth	+593.94%	n/a	n/a	n/a	n/a	n/a

Revenue by Geography

Quarter	Dec 31, 2023
International Revenue	3.22M
International Revenue Growth	n/a
Worldwide Revenue	92.00M
Worldwide Revenue Growth	n/a

Operating Expense Breakdown

Quarter	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019	Dec 31, 2018	Sep 30, 2018	Jun 30, 2018	Mar 31, 2018	Dec 31, 2017	Sep 30, 2017	Jun 30, 2017	Mar 31, 2017	Dec 31, 2016	Sep 30, 2016	Jun 30, 2016	Mar 31, 2016	Dec 31, 2015	Sep 30, 2015	Jun 30, 2015	Mar 31, 2015
Selling, General, and Administrative Revenue	41.97M	38.72M	34.50M	31.06M	26.50M	36.38M	29.65M	22.50M	17.50M	14.97M	22.50M	37.40M	34.90M	41.03M	34.27M	49.67M	39.91M	15.99M	16.24M	8.54M	4.40M	4.07M	3.83M	3.12M	1.61M	6.57M	9.46M	5.34M	6.29M	3.02M	7.33M	2.65M	4.09M	3.09M	2.80M	3.95M	2.33M	7.25M	6.36M
Selling, General, and Administrative Revenue Growth	+8.39%	+12.23%	+11.07%	+17.21%	-27.16%	+22.69%	+31.76%	+28.57%	+16.95%	-33.50%	-39.83%	+7.16%	-14.95%	+19.72%	-31.00%	+24.44%	+149.67%	-1.56%	+90.07%	+94.36%	+8.06%	+6.19%	+22.83%	+93.49%	-75.47%	-30.51%	+77.19%	-15.14%	+107.96%	-58.74%	+176.41%	-35.10%	+32.00%	+10.54%	-29.16%	+69.95%	-67.91%	+13.93%	n/a
Research and Development Revenue	20.14M	17.56M	32.72M	17.45M	11.84M	22.46M	14.29M	29.64M	17.55M	24.55M	46.15M	57.66M	51.97M	37.85M	55.58M	37.15M	45.85M	34.90M	34.04M	29.45M	56.50M	31.51M	30.90M	51.07M	32.75M	37.81M	32.16M	25.74M	25.33M	25.44M	20.38M	21.41M	20.88M	12.97M	11.23M	13.73M	11.54M	9.90M	8.28M
Research and Development Revenue Growth	+14.71%	-46.35%	+87.53%	+47.40%	-47.29%	+57.20%	-51.79%	+68.84%	-28.49%	-46.81%	-19.97%	+10.96%	+37.28%	-31.89%	+49.62%	-18.97%	+31.38%	+2.51%	+15.58%	-47.87%	+79.29%	+2.00%	-39.50%	+55.92%	-13.38%	+17.58%	+24.96%	+1.58%	-0.41%	+24.85%	-4.85%	+2.57%	+61.01%	+15.46%	-18.18%	+18.96%	+16.52%	+19.60%	n/a